Cystatin C, a novel cardiometabolic risk marker in women with polycystic ovary syndrome

• Published in: Gynecological endocrinology 2016-06, Vol.32 (6), p.457-459
• Main Authors: Yildirim, Aysegul, Yildizhan, Begum, Anik Ilhan, Gokce, Pekin, Tanju
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; Cardiovascular Diseases - blood; Cystatin C; Cystatin C - blood; Female; Humans; metabolic syndrome; Metabolic Syndrome - blood; Metabolic Syndrome - urine; microalbuminuria; polycystic ovary syndrome; Polycystic Ovary Syndrome - blood; Polycystic Ovary Syndrome - urine; urinary albumin excretion; Young Adult
• ISSN: 0951-3590; 1473-0766
• DOI: 10.3109/09513590.2015.1130807

Objective: To investigate the impact of urinary albumin excretion (UAE) and cystatin C on the metabolic components of polycystic ovary syndrome (PCOS). Methods: Seventy-five women with PCOS were divided into two groups according to metabolic syndrome as MetS + and MetS−. Clinical, metabolic and renal parameters were compared between the groups. Correlation analyses were performed between cystatin C, microalbuminuria and clinical and metabolic parameters in women with PCOS. Results: Waist/hip ratio (WHR), body mass index, LDL cholesterol, triglyceride, total cholesterol, cystatin C, UAE were significantly higher in the MetS + group compared with the MetS − one. HDL cholesterol was significantly higher in the MetS − group than the MetS + one. The UAE positively correlates with LDL cholesterol, triglyceride and total cholesterol levels. Cystatin C positively correlates with UAE, WHR, LDL cholesterol, triglyceride, total cholesterol levels. Conclusions: Evaluating UAE and cystatin C may be important for the detection of target subjects at high risk for future metabolic syndrome and cardiovascular disease.